Rising health care costs have been prioritized in the budget planning of all Western countries. Rising R&D costs of up to $800 million per marketed new pharmaceutical have dramatically reduced the approval of new chemical entities (NCEs). Globalization of diseases like AIDS and SARS has had a ...
Serving patients in more than 50 countries, we are fully dedicated to helping those living with diseases which have a large unmet medical need. Read more What we doWe embrace the rare At Immedica, we are specialists in the rare. We believe that there is a need for a pharmaceutical company...
Understandably, pharmaceutical innovation is predominantly fuelled by commercial interests. However, this focus can create a misalignment with urgent societal health needs. Therefore, rethinking our approach to incentivizing innovation is crucial, especially in underserved areas. A key element of this shift...
As these unmet needs in the field of rheumatic diseases have been identified based on consensus of expert clinicians and scientists in the field, this document may serve individual researchers, institutions and industry to help prioritise their scientific activities....
Lakewood-Amedex, Inc. is focused on developing the next-generation of topical antimicrobials to address some of the most significant unmet medical needs in the treatment of infectious diseases.
promotion of the drug will increase disease awareness, and the success encourages others in the industry to continue and expand their PMR research. However, the proportion of patients who can benefit from the drug is limited. Significant unmet needs remain for all persons suffering from...
debating the potential contribution of modern and cutting-edge manufacturing technologies to the solution of unmet production needs. Technological and regulatory aspects will be considered outlining the potential role of advanced manufacturing techniques in the advancement of PLA/PLGA MP production processes....
across Canada. Thanks to CQDM's unique mentoring program, these researchers will also have the opportunity to collaborate with senior scientists from the pharmaceutical industry who bring industrial expertise and support to the projects, to help better align research with the needs of industry and ...
Committed to addressing underserved needs through innovation with the goal to become the leader in number of 505(b)(2) value-added medicines in development. Learn More Investor relations + Faster innovation at a much lower cost and risk to drive continuous growth and create shareholders’ value....
Orphelion Pharmaceuticals AB is a Swedish limited liability company (Sw. Aktiebolag) poised to develop pharmaceuticals for unmet medical needs in animal care.The company’s senior management team have significant experience from the entire pharma value chain – from research through to registration, pri...